| 1 |
Clozapine oral suspension (Versacloz™): a guide to its use in the USA |
|
|
| Katherine A. Lyseng-Williamson |
|
| Drugs & Therapy Perspectives. 2014; 30(6): 193 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 2 |
Making clozapine safer: current perspectives on improving its tolerability |
|
|
| Bosky Nair,James Hunter MacCabe |
|
| Future Neurology. 2014; 9(3): 313 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 3 |
Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy |
|
|
| Debbi A. Morrissette,Stephen M. Stahl |
|
| CNS Spectrums. 2014; 19(05): 439 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 4 |
Clozapine: A guide to its use in patients with schizophrenia who are unresponsive to or intolerant of other antipsychotic agents |
|
|
| Lyseng-Williamson, K.A. |
|
| Drugs and Therapy Perspectives. 2013; 29(6): 161-165 |
|
| [Pubmed] [Google Scholar] |
|
| 5 |
Polypharmacy in psychiatry: A review |
|
|
| Kukreja, S. and Kalra, G. and Shah, N. and Shrivastava, A. |
|
| Mens Sana Monographs. 2013; 11(1): 82-99 |
|
| [Pubmed] [Google Scholar] |
|
| 6 |
Intracellular pathways of antipsychotic combined therapies: Implication for psychiatric disorders treatment |
|
|
| Andrea de Bartolomeis,Livia Avvisati,Felice Iasevoli,Carmine Tomasetti |
|
| European Journal of Pharmacology. 2013; 718(1-3): 502 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
